Approval of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2026 and other items .

VIVANZA BIOSCIENCES LIMITED Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054. Phone: 079-26870953, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com CIN: L24105GJ1982PLC005057 Date: 07th August, 2026 Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai — 400001 Maharashtra, India BSE Scrip Code- 530057 ISIN: INE984E01035 Subject: Outcome of Board of Directors Meeting of Vivanza Biosciences Limited (“the Company”) Dear Sir/Madam, Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), we wish to inform you that the Board of Directors of the Company at its meeting held today, i.e. Friday, 07th August, 2026, at the Registered Office of the Company, has inter alia considered and approved the following businesses: 1. Approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June, 2026, together with the Limited Review Report (Annexure –A). 2. The Board took note of the disclosure of interest received from the Directors pursuant to Section 184 of the Companies Act, 2013 and the intimation of disqualification under Section 164 of the Companies Act, 2013. 3. The Board took note of the declarations received from the Independent Directors confirming that they meet the criteria of independence as prescribed under Section 149(7) of the Companies Act, 2013 and Regulation 25(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting of Board of Directors of the Company commenced at 12:45 P.M. and concluded at 13:00 P.M. You are requested to kindly take the same on record and acknowledge. Thanking You. For, Vivanza Biosciences Limited JAYENDRA MEHTA MANAGING DIRECTOR DIN: 08210602 Encl: As above